Deleterious effects of high concentrations of (-)-epigallocatechin-3- gallate and atorvastatin in mice with colon inflammation

Nutrition and Cancer

Volumn 64, Issue 6, 2012, Pages 847-855

  Guan, Fei ^a   Liu, Anna B ^a   Li, Guangxun ^a   Yang, Zhihong ^a   Sun, Yuhai ^a   Yang, Chung S ^a   Ju, Jihyeung ^b  

^a RUTGERS UNIVERSITY   (United States)

^b Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZOXYMETHANE; DEXTRAN SULFATE; EPIGALLOCATECHIN GALLATE; LEUKOTRIENE B4; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COLITIS; COLON TUMOR; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; RECTUM HEMORRHAGE; WEIGHT REDUCTION;

ANIMALS; AZOXYMETHANE; CATECHIN; COLITIS; COLON; COLONIC NEOPLASMS; DEXTRAN SULFATE; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPTANOIC ACIDS; LEUKOTRIENE B4; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; PYRROLES; RECTUM; WEIGHT LOSS;

EID: 84865206241     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.695424     Document Type: Article

References (68)

1. Lambert, J D, Hong, J, Yang, G Y, Liao, J, and, Yang, C S. 2005. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr, 81: 284S-291S.
2. Yang, C S, and, Wang, Z Y. 1993. Tea and cancer. J Natl Cancer Inst, 85: 1038-1049. (Pubitemid 23199184)
3. Yang, C S, Maliakal, P, and, Meng, X. 2002. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol, 42: 25-54. (Pubitemid 34160518)
4. Yang, C S, Wang, X, Lu, G, and, Picinich, S C. 2009. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer, 9: 429-439.
5. /+mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res, 65: 10623-10631. (Pubitemid 41743758)
6. Ju, J, Liu, Y, Hong, J, Huang, M T, Conney, A H. 2003. Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model. Nutr Cancer, 46: 172-178. (Pubitemid 37500509)
7. Shimizu, M, Shirakami, Y, Sakai, H, Adachi, S, Hata, K. 2008. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila), 1: 298-304.
8. Shirakami, Y, Shimizu, M, Tsurumi, H, Hara, Y, Tanaka, T. 2008. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Report, 1: 355-361.
9. Xiao, H, Hao, X, Simi, B, Ju, J, Jiang, H. 2008. Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis, 29: 113-119. (Pubitemid 351201749)
10. Kawata, S, Takaishi, K, Nagase, T, Ito, N, Matsuda, Y. 1990. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res, 50: 3270-3273. (Pubitemid 20190129)
11. Caruso, M G, Notarnicola, M, Santillo, M, Cavallini, A, and, Di Leo, A. 1999. Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res, 19: 451-454. (Pubitemid 29168276)
12. Blais, L, Desgagne, A, and, LeLorier, J. 2000. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med, 160: 2363-2368.
13. Buchwald, H. 1992. Cholesterol inhibition, cancer, and chemotherapy. Lancet, 339: 1154-1156.
14. Larsson, O. 1996. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol, 22: 197-212. (Pubitemid 26173118)
15. Kusama, T, Mukai, M, Iwasaki, T, Tatsuta, M, Matsumoto, Y. 2002. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology, 122: 308-317. (Pubitemid 34116983)
16. Wachtershauser, A, Akoglu, B, and, Stein, J. 2001. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis, 22: 1061-1067. (Pubitemid 32633605)
17. Jones, K D, Couldwell, W T, Hinton, D R, Su, Y, He, S. 1994. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun, 205: 1681-1687.
18. Kawata, S, Nagase, T, Yamasaki, E, Ishiguro, H, and, Matsuzawa, Y. 1994. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer, 69: 1015-1020. (Pubitemid 24161851)
19. Horiguchi, A, Sumitomo, M, Asakuma, J, Asano, T, and, Hayakawa, M. 2004. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res, 10: 8648-8655. (Pubitemid 40053433)
20. Wejde, J, Blegen, H, and, Larsson, O. 1992. Requirement for mevalonate in the control of proliferation of human breast cancer cells. Anticancer Res, 12: 317-324.
21. Cho, S J, Kim, J S, Kim, J M, Lee, J Y, Jung, H C. 2008. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer, 123: 951-957.
22. Teraoka, N, Mutoh, M, Takasu, S, Ueno, T, Yamamoto, M. 2011. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila), 4: 445-453.
23. Hawk, M A, Cesen, K T, Siglin, J C, Stoner, G D, and, Ruch, R J. 1996. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett, 109: 217-222. (Pubitemid 27026220)
24. Shibata, M A, Kavanaugh, C, Shibata, E, Abe, H, Nguyen, P. 2003. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis, 24: 453-459. (Pubitemid 36432640)
25. Bjorkhem-Bergman, L, Acimovic, J, Torndal, U B, Parini, P, and, Eriksson, L C. 2010. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res, 30: 1105-1112.
26. Lubet, R A, Boring, D, Steele, V E, Ruppert, J M, Juliana, M M. 2009. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res (Phila), 2: 161-167.
27. Toyoda, T, Tsukamoto, T, Takasu, S, Hirano, N, Ban, H. 2009. Pitavastatin fails to lower serum lipid levels or inhibit gastric carcinogenesis in helicobacter pylori-infected rodent models. Cancer Prev Res (Phila), 2: 751-758.
28. Finlay, G A, Malhowski, A J, Polizzi, K, Malinowska-Kolodziej, I, and, Kwiatkowski, D J. 2009. Renal and liver tumors in Tsc2(+/) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther, 8: 1799-1807.
29. Browning, D R, and, Martin, R M. 2007. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer, 120: 833-843. (Pubitemid 46175404)
30. Kuoppala, J, Lamminpaa, A, and, Pukkala, E. 2008. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer, 44: 2122-2132.
31. Bardou, M, Barkun, A, and, Martel, M. 2010. Effect of statin therapy on colorectal cancer. Gut, 59: 1572-1585.
32. Jacobs, E J, Newton, C C, Thun, M J, and, Gapstur, S M. 2011. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res, 71: 1763-1771.
33. Lee, J E, Baba, Y, Ng, K, Giovannucci, E, Fuchs, C. 2011. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila), 16: 16
34. Lu, G, Xiao, H, You, H, Lin, Y, Jin, H. 2008. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res, 14: 4981-4988.
35. Terzic, J, Grivennikov, S, Karin, E, and, Karin, M. 2010. Inflammation and colon cancer. Gastroenterology, 138: 2101-2114. e2105
36. Ohkusa, T. 1985. Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora. Nihon Shokakibyo Gakkai Zasshi, 82: 1327-1336. (Pubitemid 15030050)
37. Okayasu, I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98: 694-702. (Pubitemid 20069706)
38. Yamada, M, Ohkusa, T, and, Okayasu, I. 1992. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut, 33: 1521-1527.
39. Hirono, I, Kuhara, K, Yamaji, T, Hosaka, S, and, Golberg, L. 1982. Induction of colorectal squamous cell carcinomas in rats by dextran sulfate sodium. Carcinogenesis, 3: 353-355. (Pubitemid 12088648)
40. Tamaru, T, Kobayashi, H, Kishimoto, S, Kajiyama, G, Shimamoto, F. 1993. Histochemical study of colonic cancer in experimental colitis of rats. Dig Dis Sci, 38: 529-537. (Pubitemid 23087130)
41. Cooper, H S, Murthy, S, Kido, K, Yoshitake, H, and, Flanigan, A. 2000. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis, 21: 757-768. (Pubitemid 30214034)
42. Tanaka, T, Kohno, H, Suzuki, R, Yamada, Y, Sugie, S. 2003. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci, 94: 965-973. (Pubitemid 37508979)
43. Welch, C L, and, Young, D S. 1983. Spectrophotometry of occult blood in feces. Clin Chem, 29: 2022-2025. (Pubitemid 14203603)
44. Ju, J, Hao, X, Lee, M J, Lambert, J D, Lu, G. 2009. A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice. Cancer Prev Res (Phila), 2: 143-152.
45. Swamy, M V, Patlolla, J M, Steele, V E, Kopelovich, L, Reddy, B S. 2006. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res, 66: 7370-7377. (Pubitemid 44197721)
46. Weisburger, J H, Rivenson, A, Aliaga, C, Reinhardt, J, Kelloff, G J. 1998. Effect of tea extracts, polyphenols, and epigallocatechin gallate on azoxymethane-induced colon cancer. Proc Soc Exp Biol Med, 217: 104-108.
47. Hirose, M, Hoshiya, T, Mizoguchi, Y, Nakamura, A, Akagi, K. 2001. Green tea catechins enhance tumor development in the colon without effects in the lung or thyroid after pretreatment with 1,2-dimethylhydrazine or 2,2-dihydroxy-di-n-propylnitrosamine in male F344 rats. Cancer Lett, 168: 23-29. (Pubitemid 32463908)
48. Kim, M, Murakami, A, Miyamoto, S, Tanaka, T, and, Ohigashi, H. 2010. The modifying effects of green tea polyphenols on acute colitis and inflammation-associated colon carcinogenesis in male ICR mice. Biofactors, 36: 43-51.
49. Kimball, E S, Schneider, C R, Wallace, N H, and, Hornby, P J. 2006. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol, 291: G364-G371.
50. Kverka, M, Rossmann, P, Tlaskalova-Hogenova, H, Klimesova, K, Jharap, B. 2011. Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. BMC Gastroenterol, 11: 47
51. Huang, X L, Xu, J, Zhang, X H, Qiu, B Y, Peng, L. 2011. PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis. Inflamm Res, 60: 727-734.
52. Silverstone, H, Solomon, R D, and, Tannenbaum, A. 1952. Relative influences of natural and semipurified diets on tumor formation in mice. Cancer Res, 12: 750-756.
53. Sparnins, V L, Venegas, P L, and, Wattenberg, L W. 1982. Glutathione S-transferase activity: enhancement by compounds inhibiting chemical carcinogenesis and by dietary constituents. J Natl Cancer Inst, 68: 493-496. (Pubitemid 12156689)
54. Li, Y, Innocentin, S, Withers, D R, Roberts, N A, Gallagher, A R. 2011. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell, 147: 629-640.
55. Ni, J, Chen, S F, and, Hollander, D. 1996. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut, 39: 234-241. (Pubitemid 26276001)
56. Kitajima, S, Takuma, S, and, Morimoto, M. 1999. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim, 48: 137-143. (Pubitemid 129558679)
57. Egger, B, Bajaj-Elliott, M, MacDonald, T T, Inglin, R, Eysselein, V E. 2000. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion, 62: 240-248.
58. Dieleman, L A, Ridwan, B U, Tennyson, G S, Beagley, K W, Bucy, R P. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology, 107: 1643-1652. (Pubitemid 24357616)
59. Kitajima, S, Takuma, S, and, Morimoto, M. 1999. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. J Vet Med Sci, 61: 67-70. (Pubitemid 129581167)
60. Berndt, B E, Zhang, M, Chen, G H, Huffnagle, G B, and, Kao, J Y. 2007. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol, 179: 6255-6262.
61. Kostadinova, F I, Baba, T, Ishida, Y, Kondo, T, Popivanova, B K. 2010. Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice. J Leukoc Biol, 88: 133-143.
62. Kwon, K H, Ohigashi, H, and, Murakami, A. 2007. Dextran sulfate sodium enhances interleukin-1 beta release via activation of p38 MAPK and ERK1/2 pathways in murine peritoneal macrophages. Life Sci, 81: 362-371. (Pubitemid 47077428)
63. Ohkawara, T, Takeda, H, Nishihira, J, Miyashita, K, Nihiwaki, M. 2005. Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin Exp Immunol, 141: 412-421. (Pubitemid 41075864)
64. Ohkawara, T, Nishihira, J, Takeda, H, Hige, S, Kato, M. 2002. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology, 123: 256-270. (Pubitemid 34747546)
65. Ohkawara, T, Miyashita, K, Nishihira, J, Mitsuyama, K, Takeda, H. 2005. Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol, 140: 241-248. (Pubitemid 40559149)
66. Sakagami, H, Takeda, M, Sugaya, K, Omata, T, Takahashi, H. 1995. Stimulation by epigallocatechin gallate of interleukin-1 production by human peripheral blood mononuclear cells. Anticancer Res, 15: 971-974.
67. Kang, W S, Lim, I H, Yuk, D Y, Chung, K H, Park, J B. 1999. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res, 96: 229-237.
68. Walsh, K M, Albassam, M A, and, Clarke, D E. 1996. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol, 24: 468-476. (Pubitemid 26274856)